Home › Ependymoma
Ependymoma clinical trials recruiting in the U.S.
15 studies for Ependymoma are recruiting participants at sites across the United States.
Cities with the most studies
By state
- California3 studies
- District of Columbia3 studies
- Maryland4 studies
- Massachusetts3 studies
- Pennsylvania3 studies
- Texas3 studies
Recently updated studies
Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma
RecruitingPhase 1
Ages 6 to 21 · All sexes · Updated Sep 11, 2026 · NCT07061626Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors
RecruitingPhase 2
Up to age 19 · All sexes · Updated Sep 10, 2026 · NCT01356290HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388B7-H3.CD28Z.CART in CNS Neoplasms
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Sep 3, 2026 · NCT07390539Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)
RecruitingPhase 2
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT04374305Natural History Study of Patients With Neurofibromatosis Type 2
RecruitingObservational study
Ages 8 to 75 · All sexes · Updated Sep 1, 2026 · NCT00598351PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
RecruitingPhase 1/2
Ages 18 to 120 · All sexes · Updated Aug 12, 2026 · NCT06161519Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Recruiting
12 Months – 39 Years · All sexes · Updated Aug 11, 2026 · NCT05057702Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RecruitingPhase 1/2
Ages 4 to 39 · All sexes · Updated Jul 20, 2026 · NCT05278208Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)
RecruitingPhase 1
Ages 1 to 30 · All sexes · Updated Jun 17, 2026 · NCT06193759ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors
RecruitingPhase 1
Ages 2 to 21 · All sexes · Updated Jun 11, 2026 · NCT04732065LET Optimized IMPT in Treating Pediatric Patients With Ependymoma
RecruitingPhase 1
Up to age 22 · All sexes · Updated May 20, 2026 · NCT03750513Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RecruitingPhase 1
Ages 1 to 26 · All sexes · Updated Apr 13, 2026 · NCT04185038Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer
RecruitingPhase 1
Ages 3 to 25 · All sexes · Updated Jan 9, 2026 · NCT05106296Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT04541082From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.